In the past week, MNMD stock has gone down by -8.29%, with a monthly decline of -21.09% and a quarterly plunge of -28.01%. The volatility ratio for the week is 15.38%, and the volatility levels for the last 30 days are 8.27% for Mind Medicine Inc The simple moving average for the past 20 days is -16.33% for MNMD’s stock, with a -26.63% simple moving average for the past 200 days.
Is It Worth Investing in Mind Medicine Inc (NASDAQ: MNMD) Right Now?
The 36-month beta value for MNMD is also noteworthy at 2.83. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for MNMD is 74.09M, and at present, short sellers hold a 15.30% of that float. The average trading volume of MNMD on April 10, 2025 was 2.01M shares.
MNMD) stock’s latest price update
Mind Medicine Inc (NASDAQ: MNMD) has seen a decline in its stock price by -10.39 in relation to its previous close of 5.68. However, the company has experienced a -8.29% decline in its stock price over the last five trading sessions. businesswire.com reported 2025-03-24 that NEW YORK–(BUSINESS WIRE)–Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 88,950 common shares of the Company (the “Options”), with an effective grant date of March 24, 2025. The Options have an exercise price e.
Analysts’ Opinion of MNMD
Many brokerage firms have already submitted their reports for MNMD stocks, with Evercore ISI repeating the rating for MNMD by listing it as a “Outperform.” The predicted price for MNMD in the upcoming period, according to Evercore ISI is $23 based on the research report published on January 28, 2025 of the current year 2025.
Chardan Capital Markets, on the other hand, stated in their research note that they expect to see MNMD reach a price target of $20. The rating they have provided for MNMD stocks is “Buy” according to the report published on December 20th, 2024.
Leerink Partners gave a rating of “Outperform” to MNMD, setting the target price at $20 in the report published on October 14th of the previous year.
MNMD Trading at -26.33% from the 50-Day Moving Average
After a stumble in the market that brought MNMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.70% of loss for the given period.
Volatility was left at 8.27%, however, over the last 30 days, the volatility rate increased by 15.38%, as shares sank -18.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.05% lower at present.
During the last 5 trading sessions, MNMD fell by -7.75%, which changed the moving average for the period of 200-days by -30.62% in comparison to the 20-day moving average, which settled at $6.09. In addition, Mind Medicine Inc saw -26.87% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MNMD starting from Barrow Robert, who sale 21,208 shares at the price of $6.74 back on Mar 25 ’25. After this action, Barrow Robert now owns 856,556 shares of Mind Medicine Inc, valued at $142,942 using the latest closing price.
Karlin Daniel, the Chief Medical Officer of Mind Medicine Inc, sale 6,836 shares at $6.74 during a trade that took place back on Mar 25 ’25, which means that Karlin Daniel is holding 446,177 shares at $46,075 based on the most recent closing price.
Stock Fundamentals for MNMD
The total capital return value is set at -0.39. Equity return is now at value -68.00, with -50.90 for asset returns.
Based on Mind Medicine Inc (MNMD), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -3.61. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -45.52.
Currently, EBITDA for the company is -103.92 million with net debt to EBITDA at 2.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.20.
Conclusion
In summary, Mind Medicine Inc (MNMD) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
